Biophysics and Nuclear Medicine

生物物理学和核医学

• 批准号: 7728799
• 负责人: Steven Mark Larson
• 金额: $ 14.23万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7728799
• 关键词: Actinium; Alpha Particles; Animals; Antibodies; Area; Arts; Autoradiography; Biodistribution; Bioluminescence; Biophysics; Bismuth; Bone Marrow Stem Cell; Brain; Breast; Cancer Patient; Cell Line; Cells; Chemistry; Clinic; Clinical; Clinical Research; Clinical Trials; Collimator; Complex; Comprehensive Cancer Center; Computer Systems; Computers; Core Facility; Count; Cyclotrons; Daughter; Dendritic Cells; Deoxyuridine; Development; Diagnostic; Discipline of Nuclear Medicine; Disseminated Malignant Neoplasm; Documentation; Drug Compounding; Drug Formulations; Equipment; Functional Magnetic Resonance Imaging; GPA33 gene; Gallium; Gamma Cameras; Grant; Green Fluorescent Proteins; Head; Histologic; Hospitals; Human; Image; Image Analysis; Imaging technology; Immune; Immunoglobulin G; Immunohistochemistry; Immunology; Indium-111; Individual; Injection of therapeutic agent; Investigational New Drug Application; Ions; Isotopes; Laboratories; Laboratory Research; Leadership; Life; Liquid substance; Localized; Luciferases; Lung Neoplasms; Magnetic Resonance Imaging; Malignant neoplasm of thyroid; Medical; Medical Imaging; Memorial Sloan-Kettering Cancer Center; Metabolism; Methodology; Microscopy; Microtome - medical device; Monoclonal Antibodies; Neutrons; Nuclear; Operative Surgical Procedures; Optics; PET/CT scan; Patients; Physicians; Physicians' Offices; Physics; Positron-Emission Tomography; Postdoctoral Fellow; Preparation; Production; Protons; Radiochemistry; Radioimmunotherapy; Radioisotopes; Radiolabeled; Radionuclide therapy; Radiopharmaceuticals; Reading; Reagent; Records; Reporter Genes; Reporting; Research; Research Personnel; Research Support; Resolution; Resources; Scanning; Scintillation Counting; Services; Source; Spectrum Analysis; Staging; Stem cells; Sterility; Structure; TNFRSF5 gene; Testing; Therapeutic Agents; Thymidine; Thyroid carcinoma; Tissue Stains; Tissues; Tracer; Vertebral column; Week; Work; X-Ray Computed Tomography; Yttrium; authority; base; cryostat; day; deuteron; digital; dosimetry; experience; fluorescence microscope; gene therapy; imaging informatics; improved; in vivo; instrumentation; microsystems; molecular imaging; neuro-oncology; novel; oncology; optical imaging; pre-clinical; pre-clinical research; programs; quality assurance; radiochemical; radiotracer; research and development; research study; single photon emission computed tomography; solid state; technology development; tool

The Nuclear Medicine and Medical Physics CORE will provide support in nuclear medicine, medical imaging, dosimetry, immunokinetics, radiochemistry, advanced molecular imaging of stem cells, and immune cells. This CORE is a continuation from prior years of the grant, and has been in continuous operation in support of the Immunology PO1 since 1988. Resources continue to improve and now include advanced animal and human imaging facilities for imaging and experimental studies, Several large grants have provided support for imaging technology development, which have strengthened the support for this immunology PO1 core. These include: the Comprehensive Cancer Center Grant (Varmus, PI); In Vivo Celllular and Molecular Imaging Center P50,(Larson/Blasberg, Co-Pi's) the Biomedical Enginneering Partnership,(Ling, PI) and the Imaging CORE of the Breast PO1, (Larson, PI), and the Gene Therapy Program Project (Sadelain, PI). Projects 1-4 make extensive use of CORE experience and resources in planning and implementing their specific aims. In particular, the CORE will assist project 1 with the imaging and alpha dosimetry of Bismuth- 213 and Actinium-225 decay, including the complex problem of quantifying the effect of a branching cascade involving multiple daughters with differing metabolism. For project 2, the CORE will provide quantitative imaging and dosimetry of whole IgG and antibody forms of A-33, based on SPECT of Indium- 111, and PET of Gallium-66, 68 and Yttrium-86. For Project 3, transfected immune cells, especially dendritic cells will be imaged, at the histologic level and possibly non-invasively, with GFP, bioluminescence, or nuclear methodologies. For project 4, transfected bone marrow stem cells will be imaged, using a combination of bioluminescent, GFP and nuclear imaging methodologies, depending on the level of resolution required and the need for quantification.

核医学和医学物理核心将提供核医学，医学成像， 剂量测定、免疫荧光、放射化学、干细胞和免疫细胞的高级分子成像。 这一核心是前几年赠款的延续，并一直在持续运作，以支持 自1988年以来，免疫学PO 1。资源继续改善，现在包括先进的动物和 用于成像和实验研究的人体成像设备，几笔大额赠款提供了支持， 用于成像技术的开发，这加强了对这一免疫学PO 1核心的支持。 这些包括：综合癌症中心补助金（Varmus，PI）;体内细胞和分子 成像中心P50，（Larson/Blasberg，Co-Pi's）生物医学工程合作伙伴关系，（Ling，PI）和 乳腺PO 1成像核心（Larson，PI）和基因治疗计划项目（Sadelain，PI）。 项目1-4在规划和实施其 具体目标。特别是，该研究中心将协助项目1进行铋的成像和阿尔法剂量测定， 213和锕-225衰变，包括量化分支效应的复杂问题 涉及多个具有不同代谢的子体的级联反应。对于项目2，核心资源将提供 全IgG和抗体形式的A-33的定量成像和剂量测定，基于铟的SPECT， 111的PET，以及镓-66，68和钇-86的PET。对于项目3，转染的免疫细胞，特别是树突状细胞， 细胞将在组织学水平上成像，可能是非侵入性的，用GFP，生物发光，或 核方法学。对于项目4，转染的骨髓干细胞将使用 生物发光，GFP和核成像方法的组合，这取决于 所需的分辨率和量化的必要性。